Yale Cancer Center

Yale Cancer Center has appointed Ian E. Krop, MD, PhD, as Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs.

A Yale School of Medicine study showed sacituzumab govitecan could provide new options for treatment-resistant uterine cancer.

Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.

Researchers at Yale School of Medicine have identified biological markers for a rare, aggressive eye cancer that predicts secondary tumors in the liver.

Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.

Yale Cancer Center researchers publish promising study of dual inhibition of PD1 and macrophage migration inhibitory factor.

Researchers developed a way to predict how lung cancer cells will respond to different therapies, allowing for more effective individualized treatment.

Tracy Battaglia, MD, MPH, joined Yale Cancer Center’s Community Outreach and Engagement as associate director.

A Yale study published identified the mechanism underlying the relationship between the development of AMKL and a specific genetic alteration that occurs.

New tool by Yale researchers charts journey from pre-cancerous to advanced disease in animal models.

More than 2 dozen Yale experts are collaborating on a therapy for the most defended tumors.

A Yale study found that open-source AI tools outperformed traditional, visual methods for measuring the abundance of melanoma biomarkers.

Collaborative study investigates the unique immune features of rare cancer type, says Yale's David Braun, MD, PhD.

Yale School of Medicine announced the opening of the Yale Biomedical Imaging Institute, uniting imaging, clinical translation, and data science.

Yale Medicine was ranked third in the nation for physician practices, an annual designation by Castle Connolly.

Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.

Yale Cancer Center will share data for breakthrough and emerging cancer treatments at the AACR Annual Meeting.

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

Non-small cell lung cancer, with an EGFR mutation, tends not to respond well to immunotherapy treatments, including durvalumab.

Although use of immunotherapy near the end of life has increased over time, a closer look at the benefit of this in those with advanced cancers is needed.

A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus protein does not depend on its amino acid sequence or composition.

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology, June 2nd to June 6th at McCormick Place in Chicago, Illinois.

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Barbara Burtness, MD, has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

Continued treatment for patients with cancer near end of life delays conversations about goals of care and hospice enrollment, escalates costs, and may adversely affect the quality of care patients receive.

An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.

Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non–small cell lung cancer.

Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.